Breast cancer - HealthQuill

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

by HealthQuill
January 14, 2025
0 Comments

AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival

Climate Health Medical

Plastic pollution has increased breast cancer rates globally

HQ Team December 30, 2024: Researchers have identified a strong link between plastics and the rising incidence of breast cancer. Breast cancer has.

by HealthQuill
December 30, 2024
0 Comments

Uncategorized

Elevated β-hCG linked to BRCA1 mutations in breast cancer

Bharti Jayshankar December 16, 2024: Researchers at the Rajiv Gandhi Biotechnology Centre, Kerala, delving into the molecular mechanisms of tumorigenesis by BRCA1 gene,.

by HealthQuill
December 16, 2024
0 Comments

Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of its breast cancer therapy, Keytruda.

Drugs Pharma

AstraZeneca, Merck announce promising results for breast cancer in trial 3

Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.

by HealthQuill
December 13, 2024
0 Comments

Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage and has stopped its ongoing trial.

Health Pharma

New study finds some healthy breast cells may harbor cancer cells

Bharti Jayshankar November 30, 2024: A study done by the University of Texas MD Anderson Cancer Center revealed that some breast cells in healthy.

by HealthQuill
November 30, 2024
0 Comments

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.

Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

by HealthQuill
October 1, 2024
0 Comments

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.

Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

by HealthQuill
September 30, 2024
0 Comments

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of an absence of cancer in treated patients.

Drugs Health Pharma

Henlius, Organon trial drug meets goal of an absence of breast cancer

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.

by HealthQuill
September 30, 2024
0 Comments

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.

Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.